NCT07570979
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07570979
Title A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN | AUS

Facility Status City State Zip Country Details
Mass General Hospital RECRUITING Boston Massachusetts 02114 United States Details
Mary Crowley Cancer Research RECRUITING Dallas Texas 75251 United States Details
Novartis Investigative Site RECRUITING Melbourne Victoria 3000 Australia Details
Novartis Investigative Site RECRUITING Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site RECRUITING Montreal Quebec H2X 1R9 Canada Details
Novartis Investigative Site RECRUITING Würzburg Bavaria 97080 Germany Details
Novartis Investigative Site RECRUITING Dresden Saxony 01307 Germany Details
Novartis Investigative Site RECRUITING Milan MI 20162 Italy Details
Novartis Investigative Site RECRUITING Hirakata Osaka 5731191 Japan Details
Novartis Investigative Site RECRUITING Seoul 03722 South Korea Details
Novartis Investigative Site RECRUITING Seoul 05505 South Korea Details
Novartis Investigative Site RECRUITING Madrid 28034 Spain Details
Novartis Investigative Site RECRUITING Valencia 46010 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field